إعلان
إعلان

ANIK

ANIK logo

Anika Therapeutics Inc

9.50
USD
برعاية
-0.05
-0.52%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

9.52

+0.02
+0.21%

تقارير أرباح ANIK

النسبة الإيجابية المفاجئة

ANIK تفوق 23 من 40 آخر التقديرات.

57%

التقرير التالي

بيانات التقرير القادم
١٠ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$29.45M
/
-$0.21
التغير الضمني من Q3 25 (Revenue/ EPS)
+5.88%
/
+31.25%
التغير الضمني من Q4 24 (Revenue/ EPS)
-3.76%
/
-86.00%

Anika Therapeutics Inc earnings per share and revenue

On ٠٥ نوفمبر ٢٠٢٥, ANIK reported earnings of -0.16 USD per share (EPS) for Q3 25, beating the estimate of -0.27 USD, resulting in a 41.90% surprise. Revenue reached 27.82 مليون, compared to an expected 28.36 مليون, with a -1.90% difference. The market reacted with a +2.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 المحللين forecast an EPS of -0.21 USD, with revenue projected to reach 29.45 مليون USD, implying an زيادة of 31.25% EPS, and زيادة of 5.88% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Anika Therapeutics Inc reported EPS of -$0.16, beating estimates by 41.9%, and revenue of $27.82M, -1.9% below expectations.
The stock price moved up 2.28%, changed from $9.63 before the earnings release to $9.85 the day after.
The next earning report is scheduled for ١٠ مارس ٢٠٢٦.
Based on 4 المحللين, Anika Therapeutics Inc is expected to report EPS of -$0.21 and revenue of $29.45M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان